# 1. Financial Performance ## A. Key Figures * **EBITDA Margin Expansion:** **150–200 bps** YoY in India business * Core EBITDA Margin (Practice Plus): 8.5% to 9% historical range, no significant dilution post-acquisition * Net Debt/EBITDA Target: <2.5x consolidated group target * **CapEx for Expansion:** **₹3,000 Cr** (revised from prior guidance) * **Depreciation (UK):** **₹40 Cr** (post-carve-out, adjusted basis) * **Cost of Debt:** **SONIA + 200 bps** on £15 Cr borrowing ## B. Revenue Growth * **Sustained Momentum:** Like-to-like hospital revenue in India expected to maintain **strong double-digit growth** until new facilities come online, supported by stable clinical operations. ## C. Profitability Trends * **Robust Profit Growth:** India business delivered **two consecutive quarters of high profit growth**, underpinned by meaningful margin expansion. * **Acquisition Performance:** Practice Plus core margins remain within historical range; initial oversight shows **no deterioration in operational profitability** post-acquisition. * **Margin Clarity:** Prior 12% EBITDA margin reference was distorted by corporate cost allocations—adjusted view provides more accurate performance assessment. ## D. Balance Sheet Strength * **Leverage Discipline:** Group maintains focus on keeping **net debt/EBITDA below 5x** on a consolidated basis. * **Debt Structure:** New borrowing features a **2+5 amortization profile** with two-year interest-only period, supporting near-term cash flow stability. * **Transparency on Accounting:** Pre-IFRS figures and lease impacts will be **separately disclosed** during transition to ensure clarity. ## E. Cash Flow & CapEx * **Funding Plan:** Expansion CapEx of ₹3,000 Cr to be financed through **internal accruals and debt**, with India driving planned investments and UK focused on debt servicing. * **Regional CapEx Divergence:** India has a defined growth capex roadmap, while Cayman operations entail **minimal future capital outlay**. --- # 2. Segment & Geography Mix ## A. Key Figures * **Cayman Hospital Revenue:** **$45 Mn** (current run-rate) * UK Investment: GBP 183 million net (comprising GBP 150 million debt · GBP 45 million equity) * UK EBITDA Margin: 8.5–9% (core business range) * **Insurance Revenue:** **Increased** this quarter despite **wider sequential losses** due to claim volatility ## B. India Hospital Clusters * **Core Market Consolidation:** Strategic focus on scaling domestic volumes and revenues in **Bangalore, Delhi, and high-potential cities** (Raipur, Ahmedabad, Jaipur, Mumbai) driving improved realizations and margins. * **Expansion with Infrastructure Upside:** Aggressive capacity build in **Bangalore (900 beds over 4 years)** and **Raipur**, supported by **four new Da Vinci robots**, to enhance service capability and narrow ARPP gaps. * **Flagship Development in Kolkata:** Rajarhat health city to mirror Bangalore’s model, though margin impact will be tempered by legacy assets in the cluster. ## C. UK Operations * **Margin Profile Anchored by Local Dynamics:** UK profitability remains structurally lower than Cayman due to **higher doctor and employee costs as % of sales**, with core EBITDA expected to settle in **5–9% range** post-integration. * **Stable Integration Post-Acquisition:** Birmingham hospital now fully operational under new ownership, with **no major operational shocks** reported despite prior neglect; performance aligns with expectations. * **Market Share Growth as Path to Scale:** Expansion in private healthcare segment is key lever for improving UK margins, supported by fully localized medical and administrative teams. ## D. Cayman & Insurance * **Insurance Growth Amid Volatility:** Retail productivity gains and **SME market entry** driving gross return premium growth; expansion underway in **Kolkata and Raipur**, with phase-wise rollout aligned to physical footprint. * **Segment Reporting Clarity:** Insurance business to remain **separately reported post-merger** with profitability disclosures post-integration; current profitability described as **not substantial**. * **Cayman Hospitals Show Growth Runway:** Despite strong public sector competition, $45 Mn revenue reflects **underpenetrated market share** with structural barriers limiting comparability of occupancy metrics. --- # 3. Volume & Realization Trends ## A. Key Figures * **ARPP:** **Significantly higher in Bangalore** vs. other clusters due to advanced procedures · **Discounted in Kolkata** despite operational parity * **Payer Mix:** **90%+ NHS patients in UK** vs. 30–60% at private peers, resulting in **lower revenue per patient** * **Revenue Contribution:** **Minimal non-NHS revenue** (private/self-pay) in UK business ## B. Patient Volumes * **Bangalore Outperformance:** Strong growth driven by **flagship hospital transformations**, higher bed utilization, and optimization of payor mix. * **Patient Sourcing:** Majority of patients from **within 15 km radius**, though high-end procedures (e.g., bone marrow transplants) attract pan-India demand. * **Metric Shift:** Company de-emphasizing occupancy rates in favor of **volume-driven performance metrics**, aligning with clinical rather than hospitality models. * **UK Seasonality:** Elective secondary care model ensures **minimal revenue seasonality**, with fluctuations tied to Trust contracting cycles. ## C. ARPP & Payor Mix * **Realization Growth:** Higher realizations sustained despite volume dips, powered by **payor mix optimization** and shift to premium service configurations. * **Structural Realization Gap:** Bangalore’s **advanced procedure mix** (robotic cardiac, transplants) supports persistently higher ARPP; Kolkata to remain discounted due to demographic and payer differences. * **UK Realization Headwind:** Heavy reliance on NHS funding at **lower payment rates** suppresses PPG’s UK revenue per patient versus private peers. ## D. Procedure Mix * **UK Procedure Focus:** NHS-sourced elective secondary care includes **orthopedics (joint replacements, arthroscopy), general surgery, gastroenterology, and ophthalmology**. --- # 4. Product & Specialty Performance ## A. Key Figures * **Revenue Mix Outlook:** **>50%** from cardiac and oncology combined (future) · **~1/3** of revenue from cardiac * **Oncology Growth:** **Second-highest** specialty and **fastest-growing** department * **Oncology Revenue Share:** Could increase by **up to 20%** in coming years ## B. Cardiac Services * **Margin Enhancement:** High-end robotic procedures in cardiac surgery driving improved margins and performance in the Bangalore cluster. * **UK Market Strategy:** No immediate plans to launch cardiology services; focus remains on expanding **back and spine** and **complex orthopedics** due to limited private cardiology demand outside London. ## C. Oncology Expansion * **Strategic Scaling:** Oncology to be rolled out across all hospitals with minor investments, supported by **major medical equipment upgrades** next year. * **New Ventures:** Joint venture launched with **Everhope Oncology** to establish chemotherapy centers, first operational in **Gurgaon**; additional investment in **SSO Oncology** in Mumbai, currently operating **three centers**. ## D. Elective Surgery Mix * **Pharmacy Integration:** Pharmacy business remains embedded within NHIC clinics, contributing a **high proportion of clinic revenue**, and will be scaled as part of the integrated model—**not as a standalone chain**. --- # 5. Operational Efficiency ## A. Operational Performance & Strategy * **Focus on Utilization:** Gurgaon and Delhi hospitals prioritizing bed occupancy improvement and profitability amid competitive patient acquisition challenges. * **Efficiency Model Delivering:** NH achieves **EBITDA margins close to industry levels** despite significantly lower realization rates, driven by operational streamlining, digitization, and cost discipline. * **Integrated Care Driving Results:** The **integrated care approach**—spanning hospitalization, OPD, consultations, and medicines—is resonating with customers and contributing to strong performance. ## B. Cost Optimization * **Synergy Execution Underway:** Clinic program integration with NHL expected to reduce diluted impact and enhance cost management in coming quarters. * **India Cost Discipline:** Doctor costs as a % of payouts have improved in India, while consolidated increases reflect UK operations inclusion. * **Cost Trends Stabilizing:** Doctor and employee costs are **almost flat QoQ**, with YoY improvements reflecting prior optimization efforts. * **Targeted Cost Reduction:** **Non-doctor employee expenses** offer greater reduction potential via software-driven operational efficiencies; doctor cost reduction in UK remains a mid-to-long-term goal via payor mix and clinical efficiency. * **Low-Hanging Fruit Identified:** Multiple quick-win initiatives identified for early execution, with timelines and impact to crystallize over coming quarters. ## C. Technology Integration * **Scalable Model Replication:** The successful **Bangalore cluster model**—focused on volume consolidation and payor mix optimization—is being rolled out across eastern and northern clusters. * **UK Integration on Track:** Proven technology and operational platforms from Cayman and India are being deployed across UK operations, with **bulk of CapEx in Birmingham completed** and only minor equipment pending. * **Digital Transformation Scoped:** Process changes, digital applications, and transformation initiatives have been mapped; implementation complexity will become clearer in next few quarters. --- # 6. Risks & Healthcare Factors ## A. Key Figures * **NHS Waiting Times:** **18–20 weeks or more** for elective procedures * **Senior Doctor Attrition:** **High single digits** (low relative to peers) * **UK Debt:** **GBP 15 Cr** to be repaid over **7 years** (2 + 5 year schedule) ## B. Payor Reimbursement * **Northern Cluster Pressure:** Soft growth due to **receivable issues** and **reimbursement caps**, leading to deliberate de-emphasis on scheme-based volumes to protect margins. * **CGHS Impact Minimal:** Limited exposure in Delhi renders recent rate hikes **non-material** to India operations. * **UK Payor Opportunity:** Persistent NHS waiting lists create **latent demand** for private care, especially in joint replacements, cataracts, and general surgery. ## C. Competition & Entry * **Regional Volume Headwinds:** New hospital entries in **northern India** and **Bangalore** (Sarjapur, North) are pressuring volumes and extending break-even timelines. * **Gurgaon Intensification:** Expansion by large players is challenging existing operations, with **incremental beds diluting near-term occupancy**, though long-term demand absorption is expected. * **Structural Demand Cushion:** Despite rising competition, **organized hospital supply remains below demand**, supporting recovery and stable long-term outlook. ## D. Integration Challenges * **Unmet Demand Driver:** A major portion of healthcare need goes unaddressed due to **lack of awareness or access**, representing a long-term growth runway. * **UK Margin Trajectory:** Birmingham asset losses are **winding down**, with further improvement expected to support margin expansion. * **ROCE Path in UK:** Initial dilution anticipated from acquisition scale, but **leveraged buyout** and **asset-light model** position UK business for **stronger ROCE over time**. --- # 7. Guidance & Outlook ## A. Financial & Strategic Outlook * **Breakeven Undetermined:** Insurance and clinics segment remains in investment phase with no clear breakeven timeline; peak losses may be behind. * **Growth Trajectory Intact:** Double-digit revenue growth expected to continue through FY29, supported by strong hospital performance despite quarterly volatility. * **Margin Stability Targeted:** Management aims to preserve recent margin gains in India, though near-term dilution is expected from clinic expansion investments. * **UK Integration on Track:** Birmingham turnaround expected within one year, with **positive early changes observed** after half the period; full benefits anticipated within 2–3 years. * **EPS Neutrality Expected:** UK acquisition remains on track to be **EPS neutral to slightly positive**, excluding one-time deal costs and financing impacts. ## B. Strategic Priorities & Execution * **Shift to Quality & Integration:** Strategic focus has pivoted from bed-led expansion to building an integrated care model emphasizing quality, trust, and patient proximity within **25 minutes of an NH Centre**. * **Insurance Growth Maturing:** Rapid expansion of insurance book complete; focus shifts to **optimizing underwriting, clinical decisions, and operations** to improve profitability. * **Capital Discipline Maintained:** No international acquisitions planned; primary investment focus remains **India**, with UK and Cayman operations receiving incremental support. * **Synergy Roadmap Internalized:** A structured plan for UK synergy realization exists but remains undisclosed; early benefits expected before full implementation. * **Oncology Funding Conditional:** No committed capital for new oncology ventures over next three years—future funding contingent on **performance and scalability** of current projects.